Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 28;52(1):269.
doi: 10.1007/s11033-025-10359-9.

mir-188-5p emerges as an oncomir to promote chronic myeloid leukemia via upregulation of BUB3 and SUMO2

Osman Akidan  1 , Nina Petrovic  2   3 , Sema Misir  4
Affiliations

mir-188-5p emerges as an oncomir to promote chronic myeloid leukemia via upregulation of BUB3 and SUMO2

Osman Akidan et al. Mol Biol Rep. .

Abstract

Background: Chronic myeloid leukemia (CML) is an aggressive malignancy originating from hematopoietic stem cells. miRNAs play a role in physiological and developmental processes, including cellular proliferation, apoptosis, angiogenesis, and differentiation, and in CML's prognosis, diagnosis, and treatment. This study aimed to investigate the function and possible mechanisms of action of miR-188-5p in the development and progression of chronic myeloid leukemia.

Methods and results: miRNA expression profiles were obtained from the GSE90773 dataset in the Gene Expression Omnibus (GEO). GEO2R was used to identify differentially expressed miRNAs. miRNET, miRDB, CancerSEA, GeneMANIA, and BioGRID databases were applied to assess the biological function of miRNA and target molecules in CML. RT-PCR performed validation analyses of miRNA and target molecules in CML. To determine the power of miR-188-5p expression levels to distinguish patients with CML from control, the ROC analysis was performed. miR-188-5p is significantly increased in K-562 cells, and overexpression of miR-188-5p was associated with clinicopathological features. miR-188-5p showed significantly higher AUC values (AUC = 1.0, p = 0.0001). The cut-off of miR-188-5p was 6.74. miRDB and mirNET predicted BUB3 and SUMO2 as a potential target gene of miR-188-5p. Additionally, increased expression of BUB3 and SUMO2 was observed in the K-562 cell. Bub3 is implicated in apoptosis and the cell cycle, whereas Sumo2 protein sumoylation and DNA binding are believed to contribute to catabolic processes.

Conclusions: Our results suggest that miR-188-5p acts as an oncomiRNA in CML pathogenesis and may be a promising therapeutic target for CML.

Keywords: BUB3; Chronic myeloid leukemia; SUMO2; miR-188-5p.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: Approval of the research protocol by an Institutional Reviewer Board: N/A. Informed consent: N/A. Registry and the registration no. of the study/trial: N/A. Animal studies: N/A. Competing interests: The authors declare no competing interests.

References

    1. Yeh CH, Moles R, Nicot C (2016) Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer 15:1–16 - DOI
    1. Baik H (2017) Role of the SUMO pathway in Acute Myeloid Leukemias response to treatments Doctoral dissertation, Université Montpellier
    1. Parsa-Kondelaji M, Musavi M, Barzegar F et al (2023) Dysregulation of miRNA expression in patients with chronic myelogenous leukemia at diagnosis: a systematic review. Biomark Med 17(24):1021–1029 - DOI - PubMed
    1. Pinnenti M, Sami MA, Hassan U (2024) Enabling biomedical technologies for chronic myelogenous leukemia (CML) biomarkers detection. Biomicrofluidics 18(1)
    1. Zhang X, Ma W, Xue W et al (2024) miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34 + cells partially via SERPINE1. Cell Mol Life Sci 81(1):10 - DOI

MeSH terms

Substances

LinkOut - more resources